Tech Company Financing Transactions
Oryon Cell Therapies Funding Round
Oryon Cell Therapies, based in Redwood City, secured $21 million from Byers Capital and private investors.
Transaction Overview
Company Name
Announced On
3/23/2026
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support completion of an ongoing Phase 1b/2a clinical trial of its lead neuron replacement therapy program, as well as the manufacturing scale-up and regulatory engagement needed to advance to a Phase 3 trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
303 Twin Dolphin Drive 600 � #1320
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Undisclosed
Website
Email Address
Overview
Oryon Cell Therapies is a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders. Oryon is advancing a neuron replacement technology designed to restore neural circuitry. Unlike symptomatic therapies, this therapeutic approach is intended to produce durable biological restoration in neurodegenerative disorders, in which neuronal loss is well defined and directly linked to clinical impairment. The company's initial program is in Parkinson's disease.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 3/23/2026: Grub Lab venture capital transaction
Next: 3/23/2026: Zipline venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








